Open original FDA record ↗Recall record
- FDA identifier
- Z-2715-2026
- Company in FDA record
- Biomerieux Inc
- FDA classification date
- Jul 9, 2026
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Potential for false resistant carbapenem and/or cephalosporin results when analyzing samples with kits from affected lot that have pouch foil fractures.
Source facts
- Action
- Firm began notifying customers on June 4, 2026. Customers are instructed to dispose of pouches from the affected lot (Ref 424620, Lot 0853293604). Customer may choose to inspect each pouch in their inventory and only dispose of those with "P7" on the label, or they may choose to dispose of all cards from Lot 0853293604 in their inventory. Based on individual customer policy, customers may wish to perform retrospective review of resistant results. Customers should distribute the information to all appropriate personnel in their laboratory. If product was transferred or further distributed, customer should notify downstream users/accounts.
- Initiated
- 2026-06-04
- Root cause
- Process change control
- Distribution
- International distribution to the countries of Belgium and the Netherlands.
- Recall number
- Z-2715-2026
- Recall status
- Open, Classified
- CDRH record ID
- 221078
- FDA classified
- 2026-07-09
- Recall event number
- 99213